XNAS
ZURA
Market cap394mUSD
Oct 08, Last price
4.13USD
1D
-0.96%
1Q
-19.18%
IPO
-42.96%
Name
Zura Bio Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0
Net income
-69m
L+31.00%
CFO
-65m
L+130.86%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
JATT II Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in healthcare and healthcare-related businesses. The company was incorporated in 2026 and is based in Westfield, New Jersey.
Key people
Eric Hyllengren
Chief Financial Officer · since 2025
Gary Whale
Chief Technology Officer · since 2023
Kiran Nistala
Chief Medical Officer, Head of Development · since 2024
Kim Davis
Interim Chief Executive Officer, Interim Principal Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary · since 2025
Someit Sidhu
Director · since 2024
Dan Becker
Independent Director · since 2025
Neil Graham
Independent Director · since 2023
Jennifer Jarrett
Independent Director · since 2023
Sandeep Kulkarni
Independent Director · since 2023
Amit Munshi
Independent Chairman of the Board · since 2023
Steve Schoch
Independent Director · since 2023
Parvinder Thiara
Independent Director · since 2023
Headquarters & legal address
C/O Maples Corporate Services Limited
PO Box 309
Ugland House
Grand Cayman
George Town KY1-1104
KY
PO Box 309
Ugland House
Grand Cayman
George Town KY1-1104
KY
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2022‑03 | 2021‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||